Insights from ligand and structure based methods in virtual screening of selective Ni-peptide deformylase inhibitors

Cohen ML (1992) Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050–1055 Hayes JD, Wolf CR (1990) Molecular mechanisms of drug resistance. Biochem J 272:281–290 Spratt BG (1994) Resistance to antibiotics mediated by target alterations. Science 264:388–393 Adams JM, Capecchi M (1996) N-formylmethionyl-sRNA as the initiator of protein synthesis. Proc Natl Acad Sci USA 55:147–155 Adams JM (1968) On the release of the formyl group from nascent protein. J Mol Biol 33:571–589 Clements JM, Beckett RP, Brown A, Catlin G, Lobell M, Palan S, Thomas W, Whittaker M, Wood S, Salama S, Baker PJ, Rodgers HF, Barynin V, Rice DW, Hunter MG (2001) Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 45:563–570 Nguyen KT, Hu X, Colton C, Chakrabarti R, Zhu MX, Pei D (2003) Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry 42:9952–9958 Apfel C, Banner DW, Bur D, Dietz M, Hirata T, Hubschwerlen C, Locher H, Page MGP, Pirson W, Rosse G, Specklin JL (2000) Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem 43:2324–2331 Apfel C, Banner DW, Bur D, Dietz M, Hubschwerlen C, Locher H, Marlin F, Masciadri R, Pirson W, Stadler H (2001) 2-(2-Oxo-14-dihydro-2 H-quinazolin-3-yl)- and 2-(22-dioxo-14-dihydro-2 H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors. J Med Chem 44:1847–1852 Thorarensen A, Douglas MR, Rohrer DC, Vosters AF, Yem AW, Marshall VD, Lynn JC, Bohanon MJ, Tomich PK, Zurenko GE, Sweeney MT, Jensen RM, Nielsen JW, Seest EP, Dolak LA (2001) Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg Med Chem Lett 11:1355–1358 Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, Hayes PA, Dy BM, Heaney ML, Philips MR, Bornmann WG, Sirotnak FM, Scheinberg DA (2004) Human mitochondrial peptide deformylase a new anticancer target of actinonin-based antibiotics. J Clin Invest 114:1107–1116 Xu Y, Lai LT, Gabrilove JL, Scheinberg DA (1998) Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res 4:171–176 Grujic M, Renko M (2002) Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 182:113–119 Apfel C, Banner DW, Bur D, Dietz M, Hirata T, Hubschwerlen C, Locher H, Page MGP (2000) Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem 43:2324–2331 Apfel C, Banner DW, Bur D, Dietz M (2001) 2-(2-Oxo-14-dihydro-2 H-quinazolin-3-yl)- and 2-(22-dioxo-14-dihydro-2 H-2lambda6-benzo[126]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors. J Med Chem 44:1847–1852 Hackbart CJ, Chen DZ, Lewis JG (2002) N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 46:2752–2764 Clemens JM, Beckett RP, Brown A (2001) Antibiotic activity and characterization of BB-3497 a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 45:563–570 East SP, Beckett RP (2004) Peptide deformylase inhibitors with activity against respiratory tract pathogens. Bioorg Med Chem Lett 14:59–62 Hu X, Nguyen KT (2003) Structure-based design of a macrocyclic inhibitor for peptide deformylase. J Med Chem 46:3771–3774 Serero A, Giglione C, Sardini A, Martinez Sanz J, Meinnel T (2003) An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J Biol Chem 278:52953–52963 Yuan Z, Trias J, White RJ (2001) Deformylase as a novel antibacterial target. Drug Discov Today 6:954–961 Jain R, Chen D, White RJ, Patel DV, Yuan Z (2005) Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem 12:1607–1621 Lee MD, Antczak C, Li Y, Sirotnak FM, Bornmann WG, Scheinberg DA (2003) A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun 312:309–315 Giglione C, Pierre M, Meinnel T (2000) Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol 36:1197–1205 Boularot A, Giglione C, Petit S, Duroc Y, Alves de Sousa R, Larue V, Cresteil T, Dardel F, Artaud I, Meinnel T (2007) Discovery and refinement of a new structural class of potent peptide deformylase inhibitors. J Med Chem 50:10–20 Cali P, Naerum L, Mukhija S, Hjelmencrantz A (2004) Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents. Bioorg Med Chem Lett 14:5997–6000 Michael HH, Cenizal T, Gutteridge S, Wayne SH, Tao Y, Totrov M, Vernon AW, Zheng Ya-jun (2004) A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. J Med Chem 47:6669–6672 Atli T, Martin RD, Douglas CR, Anne FV (2001) Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg Med Chem Lett 11:1355–1358 Valentina M, Xiaohui H, Juliet N, Kunyong Y, Andreas K (2004) Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg Med Chem Lett 14:1477–1481 Seung WY, Hee YL, Bong HC, Kyung MA, Jung SR, Young HL, Jae HK (2006) Synthesis and biological evaluation of N-Formyl hydroxylamine derivatives as potent peptide deformylase inhibitors. Bull Korean Chem Soc 27:1075–1078 Jung SY, Chang JZ, Sangku L, Jin HK, Won GK (2006) Macrolactin N, a new peptide deformylase inhibitor produced by Bacillus subtilis. Bioorg Med Chem Lett 16:4889–4892 CATALYST 4.10, Accelrys, Inc, San Diego, CA, 2005, http://www.accelrys.com/ Kurogi Y, Guner OF (2001) Pharmacophore modeling and three-dimensional database. Curr Med Chem 8:1035–1055 Funk OF, Kettmann V, Drimal J, Langer T (2004) Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists. J Med Chem 47:2750–2760 Brooks BR, Brucolleri RE, Olafson BD, States DJ, Swaminathan S, Karplus MJ (1983) CHARMM: a program for macromolecular energy. J Comput Chem 4:187–217 Guner OF (2000) Pharmacophore perception development and use in drug design. International University Line, La Jolla Sprague PW (1995) In: Muller K (ed) Perspectives in drug discovery and design, vol 3. ESCOM Science Publishers BV, The Netherlands, p 1 Smellie A, Teig SL, Towbin P (1995) Poling-promoting conformational variation. J Comput Chem 16:171–187 Santo RD, Fermeglia M, Ferrone M, Paneni MS, Costi R, Artico M, Roux A, Gabriele M, Tardif KD, Siddiqui A, Pricl S (2005) Simple but highly effective three-dimensional chemical-feature-based pharmacophore model for diketo acid derivatives as hepatitis C virus RNA-dependent RNA polymerase inhibitors. J Med Chem 48:6304–6314 Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749 Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759 Sherman W, Day T (2006) Novel procedure for modelling ligand/receptor induced fit effects. J Med Chem 49:534–553 Docherty AJ, Crabbe T, O’Connell JP, Groom CR (2003) Proteases as drug targets. Biochem Soc Symp 70:147–161